The startup’s efficiency will check buyers’ urge for food for early-stage drugmakers, as Boundless has solely superior so far as Section 1 medical trials.
More from Gwendolyn Wu
Boundless Bio breaks IPO lull with $100M fundraise
No Comments
Leave a comment Cancel